Within some seminal works, whole-exome sequencing of SCLC tumor surgical samples in a treatment-naïve population confirmed the already known genetic features of this disease, characterized by a high mutational burden (8.6 mut/Mb), universal loss-of-function mutations in TP53 and RB1 and rare actionable targetable mutations in KIT, PIK3CA, BRAF and amplification of FGFR1, SOX2 and MYC (9). The gene discussed is SOX2; the disease is small cell lung carcinoma.